G. Steven Burrill
Chief Executive Officer
G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves on the Boards of Directors of AliveCor, Catalyst Biosciences, Depomed (NASDAQ: DEPO), NewBridge, Novadaq (TSX: NDQ), Proventys, Targacept (NASDAQ: TRGT) and XDx. Previously he served as Chairman of the Boards of BioImagene, Abunda Nutrition and Pharmasset. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.
In 1995 Mr. Burrill received BIO’s “service award” for his global biotechnology leadership. In 2002 he was recognized as a biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50), and was also honored that year at the American Liver Foundation’s Annual “Salute to Excellence” Gala, which honors the best and the brightest from the Bay Area’s medical, biotech and bio-pharmaceutical industries. In 2008 he received the BayBio Pantheon DiNA lifetime achievement award for his worldwide biotech leadership; and in the same year he received the Alan Cranston Living Legend Award for his central role in advancing biomedical research globally. In 2011 he received a lifetime achievement award at Scrip Intelligence’s annual Scrip Award ceremony in London; also in 2011 he received the Breath of Life Award from the Northern California Chapter of the Cystic Fibrosis Foundation to honor him for his contributions to the life sciences industry throughout his career.
In addition to his work with leading life science companies, Mr. Burrill is a founder and currently serves as Chairman of the Board of the National Science and Technology Medals Foundation (NSTMF). Additionally, he serves as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). Mr. Burrill chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was also involved with the US-Japan Science and Technology Agreement Study of Technology Transfer Mechanisms between the US and Japan. Other not-for-profit activities include serving on the Boards of Directors of the Life Science Foundation (Chairman); the World Council for Ethical Standards (Chairman); the Vilas County (Wisconsin) Economic Development Corporation (VCEDC) (Chairman); the National Health Museum (Vice Chairman); the Bay Area Science Infrastructure Consortium; BayBio (Emeritus); California Healthcare Institute (Emeritus); The Exploratorium (Emeritus); The Kellogg Center for Biotechnology; the MIT Center for Biomedical Innovation; BIO Ventures for Global Health (BVGH); the Harvard Medical School Genetics Advisory Council and the NIH Scientific Management Review Board.
He serves on the editorial boards of Scientific American; the Journal of Commercial Biotechnology and Life Science Leader and also serves on the advisory boards of the Center for Policy on Emerging Technologies (C-PET) and BioAg Gateway, City of Madison. He is an advisor to the University of Illinois Institute for Genomic Biology, the University of Wisconsin-College of Agriculture and Life Sciences, the University of Minnesota College of Biological Sciences and Duke University, and is an adjunct professor at University of California, San Francisco. He also serves on the Advisory Boards for the Department of Biology at San Francisco State University and the Biotechnology Master’s Program in the Department of Biology at the University of San Francisco. He serves on the BioNJ Diagnostics and Personalized Medicine Committee.